Back to Search
Start Over
The complement component C5 is not responsible for the alternative pathway activity in rabbit erythrocyte hemolytic assays during eculizumab treatment.
- Source :
-
Cellular & molecular immunology [Cell Mol Immunol] 2020 Jun; Vol. 17 (6), pp. 653-655. Date of Electronic Publication: 2020 Mar 24. - Publication Year :
- 2020
- Subjects :
- Animals
Complement Pathway, Alternative drug effects
Erythrocytes drug effects
Hemolytic-Uremic Syndrome immunology
Humans
Rabbits
Antibodies, Monoclonal, Humanized pharmacology
Complement C5 metabolism
Complement Pathway, Alternative immunology
Erythrocytes metabolism
Hemolysis drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 2042-0226
- Volume :
- 17
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Cellular & molecular immunology
- Publication Type :
- Report
- Accession number :
- 32210393
- Full Text :
- https://doi.org/10.1038/s41423-020-0406-y